BioXcel Therapeutics (BTAI) Interest & Investment Income (2020 - 2026)
BioXcel Therapeutics' (BTAI) quarterly Interest & Investment Income came in at $211000.0 in Q1 2026, down 24.37% year-on-year from $279000.0 in Q1 2025, and down 34.27% quarter-over-quarter from $321000.0 in Q4 2025.
BioXcel Therapeutics (BTAI) Interest & Investment Income (2020 - 2026) Analysis & Trends
BioXcel Therapeutics' Interest & Investment Income history runs 7 years deep, the most recent figure standing at $211000.0 for Q1 2026.
- On a quarterly basis, Interest & Investment Income fell 24.37% year-over-year to $211000.0 in Q1 2026; TTM through Mar 2026 was $998000.0, a 48.4% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 59.03% from the prior year.
- Interest & Investment Income declined to $211000.0 in Q1 2026 per BTAI's latest filing, from $321000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.0 million in Q1 2023 and bottomed at $15000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $616000.0 (2024), against an average of $709235.3.
- Across the five-year window, Interest & Investment Income soared 13333.33% in 2023 and tumbled 70.54% in 2025, its largest moves.
- Year by year, Interest & Investment Income stood at $1.5 million in 2022, then slumped by 36.34% to $946000.0 in 2023, then slumped by 61.1% to $368000.0 in 2024, then slipped by 12.77% to $321000.0 in 2025, then plunged by 34.27% to $211000.0 in 2026.
- Per Business Quant, the three latest BTAI Interest & Investment Income figures stand at $211000.0 (Q1 2026), $321000.0 (Q4 2025), and $236000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | BioXcel Therapeutics | 20.57 Mn | 20.57 Mn | -77,000.00 | 211,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 211,000.00 |
| Dec 31, 2025 | 321,000.00 |
| Sep 30, 2025 | 236,000.00 |
| Jun 30, 2025 | 230,000.00 |
| Mar 31, 2025 | 279,000.00 |
| Dec 31, 2024 | 368,000.00 |
| Sep 30, 2024 | 616,000.00 |
| Jun 30, 2024 | 671,000.00 |
| Mar 31, 2024 | 947,000.00 |
| Dec 31, 2023 | 946,000.00 |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 2.02 Mn |
| Dec 31, 2022 | 1.49 Mn |
| Sep 30, 2022 | 823,000.00 |
| Jun 30, 2022 | 204,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Sep 30, 2021 | 12,000.00 |
| Jun 30, 2021 | 10,000.00 |